ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps
Emerging Company Profile: ESSA Pharma, a publically traded cancer R&D company, believes it has the answer to drug resistance in patients treated with best-selling cancer therapies Xtandi and Zytiga – as it targets last-line patients with a prostate cancer therapy based on a new mechanism of action.
You may also be interested in...
Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.